Insider Buying: Insmed Incorporated (NASDAQ:INSM) Director Buys 20,000 Shares of Stock

Insmed Incorporated (NASDAQ:INSM – Get Rating) Director Melvin Md Sharoky bought 20,000 shares of the stock in a transaction dated Wednesday, May 11th. The stock was bought at an average price of $17.20 per share, with a total value of $344,000.00. Following the acquisition, the director now owns 262,621 shares in the company, valued at approximately $4,517,081.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

INSM stock opened at $18.19 on Friday. The company has a fifty day moving average price of $22.86 and a 200 day moving average price of $25.10. Insmed Incorporated has a 12 month low of $16.41 and a 12 month high of $34.44. The company has a current ratio of 6.04, a quick ratio of 5.52 and a debt-to-equity ratio of 6.73.

Insmed (NASDAQ:INSM – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.11. The firm had revenue of $53.10 million during the quarter, compared to the consensus estimate of $53.36 million. Insmed had a negative net margin of 217.35% and a negative return on equity of 108.20%. Insmed’s revenue for the quarter was up 32.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.89) EPS. Analysts forecast that Insmed Incorporated will post -3.56 EPS for the current fiscal year.

Several research analysts have recently issued reports on INSM shares. StockNews.com started coverage on shares of Insmed in a report on Thursday, March 31st. They issued a “hold” rating for the company. SVB Leerink lowered their target price on shares of Insmed from $57.00 to $52.00 and set an “outperform” rating for the company in a report on Tuesday, February 22nd. The Goldman Sachs Group began coverage on shares of Insmed in a report on Wednesday, April 27th. They issued a “buy” rating and a $56.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Insmed from a “buy” rating to a “hold” rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $48.00.

A number of institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY raised its position in Insmed by 2.0% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 30,304 shares of the biopharmaceutical company’s stock worth $835,000 after buying an additional 596 shares during the last quarter. Advisor Group Holdings Inc. raised its position in Insmed by 56.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 2,140 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 772 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in Insmed by 1.8% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 45,142 shares of the biopharmaceutical company’s stock worth $1,230,000 after buying an additional 784 shares during the last quarter. First Republic Investment Management Inc. raised its position in Insmed by 10.7% during the 4th quarter. First Republic Investment Management Inc. now owns 8,583 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 832 shares during the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed during the 4th quarter worth $27,000.

Insmed Company Profile (Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Stories